Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Despite progress in our understanding of the biology of hepatocellular carcinoma (HCC), this tumour remains difficult-to-cure for several reasons, starting from the particular disease environment where it arises—advanced chronic liver disease—to its heterogeneous clinical and biological behaviour. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannini, Edoardo G., Aglitti, Andrea, Borzio, Mauro, Gambato, Martina, Guarino, Maria, Iavarone, Massimo, Lai, Quirino, Levi Sandri, Giovanni Battista, Melandro, Fabio, Morisco, Filomena, Ponziani, Francesca Romana, Rendina, Maria, Russo, Francesco Paolo, Sacco, Rodolfo, Viganò, Mauro, Vitale, Alessandro, Trevisani, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896125/
https://www.ncbi.nlm.nih.gov/pubmed/31671581
http://dx.doi.org/10.3390/cancers11111689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896125/
https://www.ncbi.nlm.nih.gov/pubmed/31671581
http://dx.doi.org/10.3390/cancers11111689

Ejemplares similares